NCT04571645Phase 3Terminated

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-05-16Actual

Enrollment · participants9Actual

Source updated2024-04-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Acute Myeloid Leukemia

Treatments or interventions studied

DociparstatDrugAlso known as DSTAT, CX-01, 2-0,3-0 desulfated heparin, ODSH, dociparstat sodium

Primary outcomes · main study measures

Read the study measures

measure: Overall Survival; description: Overall survival was defined for all study participants through 5 years after randomization. Overall survival was to be measured from the date of randomization to the date of death from any cause. Participants not known to have died at last follow-up contact were to be censored on the date they were last known to be alive. Due to early termination, subjects did not complete long term follow-up and efficacy (including overall survival outcome) was not analyzed.; timeFrame: Measured from randomization to date of death from any cause, up to 1 year.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history